Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Comment by CNInvestingon Aug 13, 2016 6:19pm
130 Views
Post# 25139393

RE:RE:RE:Concordia's new CFO

RE:RE:RE:Concordia's new CFOIcing indeed...MT and his croonies did with CXR the only thing he's capable of doing. Leverage to the max, buy stuff, and hike prices. Frigging loser. I'm glad that you're finally getting some recognition Lattice after all the BS people told you. Also glad I got out in June just to trade. Things got a whole lot worse since then.

LatticelnExile wrote: Borkowski has been substituting for MT in public for quite some time.  Ed was the one who presented at the RBC health conference in February, as well he did the Spring Scotia Conference last month. 

If you look on the management circular on what Borkowski is getting paid at CXR, you will see that he is a pig like all the other execs.  And, the icing .... Borkowski was a previous Controller at Biovail! 


CNInvesting wrote: Well he's the only one with experience in large pharma companies. He should actually be CEO if he's any good instead of that know-nothing Thompson. 

argentia77 wrote:

"Edward J. Borkowski has held the title of Chief Financial Officer for a myriad of multi-billion dollar healthcare organizations such as Mylan, Inc. ($5.5B) (NASDAQ: MYL), Carefusion Corporation ($3.5B), ConvaTec ($1.7B) and Amerigen Pharmaceuticals, an early stage, private, generic pharmaceutical company. During Borkowski’s seven-year tenure at Mylan, he led the company from a $900 million revenue U.S.-based firm, to one of the world leaders in generic pharmaceuticals through a series of strategic acquisitions and internally focused development of new products; it is now $5.5 billion in revenue. At CareFusion Corporation, Borkowski was tasked with taking the company public in 2010. CareFusion is now a global $3.5 billion revenue healthcare company focused on pharmaceutical dispensing equipment, infusion pumps, ventilators and surgical instruments. Borkowski was acting CFO at ConvaTec through 2013. It is now is a $1.7 billion revenue global healthcare company, private-equity owned and focused on Ostomy, wound care, surgical dressings and urology and incontinence related products."

Only time will tell if he turns this ship around.


 




<< Previous
Bullboard Posts
Next >>